The Fly

Spectrum announces Rolvedon added to latest NCCN Guidelines

Spectrum announced that Rolvedon has been added to the latest National Comprehensive Cancer Network Supportive Care Guidelines, or NCCN Guidelines, in oncology for Hematopoietic Growth Factors. The NCCN Guidelines provide recommendations for the appropriate use of growth factors in the clinical management of febrile neutropenia and now include Rolvedon as a treatment option under Management of Neutropenia: G-CSFs for Prophylaxis of Febrile Neutropenia and Maintenance of Scheduled Dose Delivery.

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on SPPI:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More